Moderna

Surgeons are frequently impatient, “never letting the skin get in the way of the problem.” One of my colleagues repeatedly asks God, "Please give me patience right away.” That seems to be the case for us that are not scientists; we often are not patient enough for the data to unfold; the data, in this case, some reliable findings on the incidence of myocarditis and pericarditis associated with the COVID vaccinations.
There has been no shortage of COVID-19 vaccine doubters. One (of the infinite number) of criticisms of the mRNA vaccines is that clinical trial data is somehow unreliable, or that the vaccine won't work in the “real world." But a study at the University of Texas Southwestern Medical Center has slammed the brakes on that theory. The Pfizer/Moderna vaccines almost entirely prevented infection in first-line medical workers.
We've finally had some amazing (and badly needed) news about COVID. Vaccines from Pfizer and Moderna are about 95 percent protective against COVID. But perhaps more importantly, according to interim analyses, Moderna's vaccine is 100% protective against severe COVID. This number is not only more impressive but may also be more clinically relevant.
Pfizer and Moderna are producing fewer but more effective (and pricier) vaccines, while AstraZeneca is making a greater number of less effective (and cheaper) vaccines.
We've just gotten a whole bunch of good news – news we really needed – about finally getting the upper hand against COVID-19. Two vaccines, both more than 90% effective at protecting clinical trial participants against the disease, were announced just seven days apart. These numbers are well beyond expectations, but some critically important questions linger. Here they are. The answers will determine how successful the vaccines will be.